一个受损的无素-蛋白酶体系统会增加APOBEC3A的丰度
Margo Coxon1, Madeline A Dennis1, Alexandra Dananberg2
1School of Molecular Biosciences, Washington State University, Pullman, WA 99164-7520, USA.
NAR cancer
|December 29, 2023
概括
蛋白质酶抑制剂增加癌细胞中的APOBEC3A (A3A) mRNA和蛋白质水平,导致更多的DNA损伤. 这表明蛋白质酶功能障碍可能会影响癌症治疗反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 在癌症中,APOBEC的cytidine deaminases有助于基因不稳定.
- 升高的APOBEC3A (A3A) 与特定的突变特征有关,但其对乳腺癌的调控尚不清楚.
研究的目的:
- 研究调节乳腺癌细胞中A3A丰富度的机制.
- 为了确定蛋白酶体抑制对A3A水平和活性的影响.
主要方法:
- 用蛋白质酶抑制剂治疗乳腺癌和多发性骨髓瘤细胞系.
- 测量A3A mRNA和蛋白质水平.
- 评估细胞增殖,DNA损伤和cytidine deaminase活动.
主要成果:
- 蛋白质酶抑制剂显著增加了A3A mRNA和蛋白质的丰度,主要是通过转录上调.
- FBXO22被确定为A3A.的转录调节中的调解者.
- 增加的A3A导致细胞因素去氨酶活性升高,增殖减少,基因组DNA损伤增加.
结论:
- 蛋白质酶抑制会触发A3A的转录性增加,从而导致遗传不稳定.
- 不调节的蛋白酶体功能,无论是固有的还是治疗性的,都可能影响A3A驱动的遗传异质性,并可能影响癌症治疗结果.
相关概念视频
The Proteasome
846
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
846
Regulated Protein Degradation
7.3K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.3K
The Unfolded Protein Response
4.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.6K
Export of Misfolded Proteins out of the ER
3.6K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.6K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K


